CLINICAL_TRIALS trial_result · 2015-06-22

Clinical Trial Update: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma [Phase 3]

Phase 3 trial evaluating rituximab in patients with low tumor burden indolent non-Hodgkin's lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Eastern Cooperative Oncology Group | Conditions: Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2015-06-22